HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Take the CME quiz: Vol. 10 No. 2, February 2009 E-Letters: Submit a response Alert me when this article is cited Alert me when E-Letters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ross, L. F. Search for Related Content PubMed Articles by Ross, L. F. Social Bookmarking                         What's this?

NeoReviews Vol.10 No.2 2009 e71
© 2009 American Academy of Pediatrics

Ethical and Policy Issues in Newborn Screening

Historical, Current, and Future Developments

^* Carolyn and Matthew Bucksbaum Professor of Clinical Ethics; Professor, Departments of Pediatrics, Medicine, and Surgery; Associate Director of the MacLean Center for Clinical Medical Ethics at the University of Chicago, Chicago, Ill

Each year, millions of infants in the United States and around the world undergo a heel stick for NBS in the first postnatal week. It began in the early 1960s with an NBS program for phenylketonuria (PKU). Dr Robert Guthrie developed both the bacterial inhibition assay (BIA) to detect high concentrations of phenylalanine as well as the filter paper on which blood spots were collected to make high-volume screening possible. NBS expanded slowly throughout the 1970s and 1980s until the application of tandem mass spectrometry, which allows for multiplex testing for many organic acid and fatty acid conditions using one sample. The controversy over whether all of the conditions that can be identified by tandem mass spectrometry should be included in a universal mandatory program was bypassed in 2005 when the Advisory Committee on Heritable Disorders in Newborns and Children endorsed the uniform panel proposed by the American College of Medical Genetics(ACMG) in collaboration with the Health Resources and Services Administration (HRSA). This article reviews several ethical controversies raised by NBS programs, both those already in place (PKU, sickle cell disease, cystic fibrosis) and those under consideration (Duchenne muscular dystrophy, fragile X). Among the controversies are the question of informed consent, whether to disclose incidental discoveries such as carrier status, whether an efficacious treatment must exist, and when to screen universally or target testing to particular populations. Several unique features of NBS apply to infants in the neonatal intensive care unit (NICU), and NBS can employ technologies other than the Guthrie card (eg, hearing screening).

Abbreviations: ACMG: American College of Medical Genetics • BIA: bacterial inhibition assay • FXTAS: fragile X tremor ataxia syndrome • HRSA: Health Resources and Services Administration • IRT: immunoreactive trypsinogen • MCAD: medium-chain acyl CoA dehydrogenase deficiency • MCW: Medical College of Wisconsin • MDA: Muscular Dystrophy Association • NARC: National Association for Retarded Children • NBS: newborn screening • NICHD: National Institute of Child Health and Human Development • NICU: neonatal intensive care unit • PCR: polymerase chain reaction • PKU: phenylketonuria • PN: parenteral nutrition • USPSTF: United States Preventive Services Task Force • WHO: World Health Organization

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?